We performed a multicenter clinical trial that included GPC3-positive refractory pediatric cancer cases (UMIN Clinical Trials Registry: 000006357) (Table 1) (34); 18 patients received GPC3 peptide vaccination. This evidence concerns the gene GPC3 and cancer.